## Conference Schedule

**Wednesday, June 15, 2011**

<table>
<thead>
<tr>
<th>TIME</th>
<th>Article/Abstract</th>
<th>TITLE, AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 08:45</td>
<td>MEET THE PROFESSOR (6 parallel sessions)</td>
<td>IX CLL FOR THE CLINICIAN (room A) M. Hallek, Cologne (Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I EPIDEMIOLOGY OF ADULT NON-HODGKIN LYMPHOMA (room B I) P. Boffetta, New York NY (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XIII THE ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF LYMPHOMA (room B II) R. Levy, Stanford, CA (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VII THE ROLE OF THE MICROENVIRONMENT IN LYMPHOID CANCERS (USI Auditorium, Lugano University) R.D. Gascoyne, Vancouver, B.C. (Canada)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V PRIMARY CNS LYMPHOMA IN IMMUNOCOMPETENT PATIENTS (USI Aula Magna, Lugano University) A.J. Ferreri, Milan (Italy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VIII RADIO-IMMUNOTHERAPY IN MALIGNANT LYMPHOMA: AN UNDERUSED TOOL? (Cittadella Theater) A. Hagenbeek, Amsterdam (Netherlands)</td>
</tr>
<tr>
<td>09:00 – 09:45</td>
<td>MEET THE PROFESSOR (6 parallel sessions)</td>
<td>VI MICRO-ARRAYS FOR DUMMIES (room A) M.F. Fey, Berne (Switzerland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XV PRIMARY CUTANEOUS LYMPHOMAS (room B I) R. Willenze, Leiden (Netherlands)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XII GRAY ZONE LYMPHOMAS: A BIOLOGICAL EXPERIMENT, AND A CHALLENGE FOR DIAGNOSIS AND MANAGEMENT (room B II) E.S. Jaffe, Bethesda, MD (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV EPIGENETICS: WHAT IT IS AND WHAT IT CAN BRING (USI Auditorium, Lugano University) M. Esteller, L'Hospitalet de Llobregat - Barcelona (Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III ROLE OF ALLOTRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA (USI Aula Magna, Lugano University) P. Dreger, Heidelberg (Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>X WHEN SHOULD RADIOTHERAPY BE USED IN LYMPHOMA? (Cittadella Theater) T. Illidge, Manchester (UK)</td>
</tr>
<tr>
<td>10:00 – 10:45</td>
<td>MEET THE PROFESSOR (6 parallel sessions)</td>
<td>II NEW PERSPECTIVES AND CHALLENGES IN THE UNDERSTANDING OF MANTLE CELL LYMPHOMA (room A) E.campo, Barcelona (Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XIV T AND NK CELL LYMPHOPROLIFERATIVE DISORDERS (room B I) S.T. Rosen, Chicago, IL (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XI DISTINGUISHING BURKITT LYMPHOMA FROM DIFFUSE LARGE B-CELL LYMPHOMA (room B II) A. Jack, Leeds (UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV EPIGENETICS: WHAT IT IS AND WHAT IT CAN BRING (USI Auditorium, Lugano University) M. Esteller, L'Hospitalet de Llobregat - Barcelona (Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V PRIMARY CNS LYMPHOMA IN IMMUNOCOMPETENT PATIENTS (USI Aula Magna, Lugano University) A.J. Ferreri, Milan (Italy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VIII RADIO-IMMUNOTHERAPY IN MALIGNANT LYMPHOMA: AN UNDERUSED TOOL? (Cittadella Theater) A. Hagenbeek, Amsterdam (Netherlands)</td>
</tr>
<tr>
<td>11:00 – 12:00</td>
<td>CONTROVERSY I: CONTROVERSIES IN FOLLICULAR LYMPHOMAS (room A, B, C and Marquee Parco Ciani)</td>
<td>Chair: T. A. Lister, London (UK)</td>
</tr>
<tr>
<td>004 – 005</td>
<td></td>
<td>a) A TREATMENT IS NECESSARY IN FL: SHOULD WE START WITH R-CT OR IS RITUXIMAB ALONE SUFFICIENT? R.I. Fisher, Rochester, NY (USA) vs M. Ghielmini, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>006 – 007</td>
<td></td>
<td>b) MAINTENANCE IN FL: RIT OR RITUXIMAB? A. Hagenbeek, Amsterdam (Netherlands) vs E. Kimby, Stockholm (Sweden)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td><strong>LUNCH TIME</strong> (Marquee Parco Ciani)</td>
<td></td>
</tr>
<tr>
<td>13:00 – 13:55</td>
<td><strong>OPENING OF THE CONFERENCE</strong> <em>(room A, B, C and Marquee Parco Ciani)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: F. Cavalli, Bellinzona (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td><strong>WELCOME AND INTRODUCTORY REMARKS</strong> <em>(Marquee Parco Ciani)</em></td>
<td></td>
</tr>
<tr>
<td>13:10</td>
<td><strong>AWARD OF THE SAN SALVATORE FOUNDATION</strong> combined with HENRY KAPLAN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MEMORIAL LECTURE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction to the Foundation: L. Butti, Lugano (Switzerland),</td>
<td></td>
</tr>
<tr>
<td></td>
<td>President of the Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presentation of the award: R.A. Stahel, Zurich (Switzerland),</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairman of the Scientific Committee</td>
<td></td>
</tr>
<tr>
<td>13:20</td>
<td><strong>HENRY KAPLAN MEMORIAL LECTURE</strong> <em>(room A, B, C and Marquee Parco Ciani)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MOLECULAR PATHOGENESIS OF B CELL LYMPHOMAS: FROM CYTOGENETICS TO GENOME SEQUENCING</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R. Dalla-Favera, New York, NY (USA)</td>
<td></td>
</tr>
<tr>
<td>14:00 – 14:45</td>
<td><strong>SESSION 1 – LYMPHOMA EPIDEMIOLOGY</strong> <em>(room A, B, C and Marquee Parco Ciani)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: D.D. Weisenburger, Omaha NE (USA)</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>008 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) CONTINUES TO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INCREASE AMONG OLDER (&gt; 65 YEARS OF AGE) PATIENTS IN THE UNITED</td>
<td></td>
</tr>
<tr>
<td></td>
<td>STATES (US) BUT NOT AMONG YOUNGER (20-64 YEARS OF AGE) PATIENTS. A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER) STUDY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B.P. O’Neill et al., Rochester, MN (USA)</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>009 PREVALENCE AND FREQUENCY OF CIRCULATING T(14;18)-POSITIVE CELLS IN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HEALTHY INDIVIDUALS OF A POPULATION-BASED CROSS SECTIONAL STUDY –</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASSOCIATION WITH AGE AND GENDER BUT NOT WITH SMOKING STATUS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Hirt et al., Greifswald (Germany)</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>010 A COMPREHENSIVE ANALYSIS OF THE UNITED STATES (US) HODGKIN LYMP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PHOMA (HL) SEER DATABASE: THE IMPACT OF RACE AND PLACE OF BIRTH ON</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INCIDENCE AND SURVIVAL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A.M. Evens et al., Worcester, MA (USA)</td>
<td></td>
</tr>
<tr>
<td>14:45 – 15:05</td>
<td><strong>COFFEE BREAK</strong> <em>(Marquee Parco Ciani)</em></td>
<td></td>
</tr>
<tr>
<td>15:05 – 16:10</td>
<td><strong>SESSION 2 - LYMPHOMA AND ITS MICROENVIRONMENT</strong> <em>(room A, B, C and Marquee Parco Ciani)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: R.D. Gascoyne, Vancouver, B.C. (CA)</td>
<td></td>
</tr>
<tr>
<td>15:25</td>
<td>012 DEFECTS AND ABNORMALITIES IN INFILTRATING T CELLS IN PATIENTS WITH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOLLICULAR LYMPHOMA AT DIAGNOSIS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Kiai et al., London (UK)</td>
<td></td>
</tr>
<tr>
<td>15:40</td>
<td>013 RITUXIMAB INFUSION INDUCES NK ACTIVATION IN LYMPHOMA PATIENTS WITH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>THE HIGH AFFINITY CD16 POLYMORPHISM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>G. Weiner et al., Iowa City, IA (USA)</td>
<td></td>
</tr>
<tr>
<td>15:55</td>
<td>014 AMD3100 DISRUPTS THE CROSS-TALK BETWEEN CHRONIC LYMPHOCYTIC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LEUKEMIA CELLS AND THEIR MICROENVIRONMENT: PRECLINICAL EVIDENCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOR ITS COMBINATION WITH CLL TREATMENTS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Stamatopoulos et al., Brussels (Belgium)</td>
<td></td>
</tr>
<tr>
<td>16:10 – 17:10</td>
<td><strong>SESSION 3 – MANTLE CELL LYMPHOMA</strong> <em>(room A, B, C and Marquee Parco Ciani)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: M. Dreyling, Munich (Germany) and M.F. Fey, Berne (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>015 DIFFERENTIAL EXPRESSION OF SOX11, HDGFPRP3, AND DBN1 IDENTIFIES TWO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SUBGROUPS OF MCL WITH DIFFERENT CLINICAL OUTCOME AND GENETIC FEATURES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Royo et al., Barcelona (Spain)</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>016 R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FIRST RESULTS OF A RANDOMIZED TRIAL FOR ELDERLY PATIENTS WITH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MANTLE CELL LYMPHOMA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J.C. Kluit-Nelemans et al., Groningen (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>16:40</td>
<td>017 PHASE II STUDY OF R-CHOP FOLLOWED BY 90Y-IBRITUMOMAB TIUXETAN IN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UNTREATED MANTLE CELL LYMPHOMA (MCL); 5 YEAR FOLLOW-UP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M.R. Smith et al., Philadelphia, PA (USA)</td>
<td></td>
</tr>
<tr>
<td>16:55</td>
<td>018 OUTCOME OF PATIENTS WITH MANTLE CELL LYMPHOMA UNDERGOING</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUTOLOGOUS VERSUS REDUCED-INTENSITY ALLOGENEIC TRANSPANTATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T.S. Fenske et al., Milwaukee, WI (USA)</td>
<td></td>
</tr>
<tr>
<td>17:30 – 18:30</td>
<td><strong>FOCUS ON… SESSIONS</strong> <em>(6 parallel sessions)</em></td>
<td></td>
</tr>
<tr>
<td>17:30 – 18:30</td>
<td><strong>UPDATE OF RANDOMISED TRIALS</strong> <em>(room A)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: R.I. Fisher, Rochester, NY (USA)</td>
<td></td>
</tr>
</tbody>
</table>
PRELIMINARY RESULTS OF QUALITY OF LIFE (QOL) ANALYSES FROM THE INTERGROUP PHASE III RANDOMISED TRIAL OF RITUXIMAB VS A WATCH AND WAIT APPROACH IN PATIENTS WITH ADVANCED STAGE, ASYMPTOMATIC, NON-BULKY FOLLICULAR LYMPHOMA (FL)
K.M. Ardeshna et al., London (UK)

IMPROVED SURVIVAL AFTER A MEDIAN FOLLOW-UP OF 6 YEARS FOR IMMUNOCHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA (FL) - UPDATE OF THE OSHO#39 TRIAL
M. Herold et al., Erfurt (Germany)

EIGHT-YEAR FOLLOW-UP OF THE GELA-GOELAMS FL2000 STUDY COMPARING CHVP-INTERFERON TO CHVP-INTERFERON PLUS RITUXIMAB IN FOLLICULAR LYMPHOMA PATIENTS
E. Buchy et al., Lyon (France)

IMPACT OF INDUCTION CHEMOTHERAPY REGIMEN ON RESPONSE, SAFETY AND OUTCOME IN THE PRIMA STUDY
F. Marschhauer et al., Lille (France)

ALTERNATING COURSES OF 3X CHOP AND 3X DHAP PLUS RITUXIMAB FOLLOWED BY A HIGH DOSE ARA-C CONTAINING MYELOABLATIVE REGIMEN AND AUTOLOGOUS STEM CELL TRANSPANTATION (ASCT) IS SUPERIOR TO 6 COURSES OF CHOP PLUS RITUXIMAB FOLLOWED BY MYELOABLATIVE RADIOTHERAPY AND ASCT IN MANTLE CELL LYMPHOMA: UPDATE OF RESULTS OF THE MCL YOUNGER TRIAL OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK (MCL NET)
O.R. Hermine et al., Paris (France)

SURVIVAL IMPACT OF DARBEPOETIN ALPHA IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH IMMUNOCHEMOTHERAPY: THE LNH03-6B GELA STUDY
R. Delarue et al., Paris (France)

RADIATION DOSE FOR LOCAL CONTROL IN NON-HODGKIN LYMPHOMA I: BRITISH NATIONAL LYMPHOMA INVESTIGATION RANDOMISED TRIAL
P. Hoskin et al., Northwood (UK)

SHOULD RADIATION THERAPY (XRT) BE THE STANDARD THERAPEUTIC APPROACH FOR STAGE I FOLLICULAR LYMPHOMA (FL)?: A COMPARATIVE EFFECTIVENESS ANALYSIS OF THE NATIONAL LYMPHOCARE STUDY (NLCS)
J.W. Friedberg et al., Rochester, NY (USA)

FOLLICULAR LYMPHOMA: CURABILITY BY RADIOTHERAPY IN LIMITED STAGE NODAL DISEASE? UPDATED RESULTS OF A RANDOMIZED TRIAL
M. Engelhard et al., Essen (Germany)

TREATMENT OF LIMITED-STAGE DLBCL CAN BE EFFECTIVELY TAILORED USING A PET-BASED APPROACH
L.H. Sehn et al., Vancouver, C.B. (Canada)

ACVBP VERSUS ACVBP PLUS RITUXIMAB FOR YOUNG PATIENTS WITH LOCALIZED LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA: A STUDY BY THE GROUPE D’ETUDE DES LYMPHOMES DE L’ADULTE
N. Ketterer et al., Lausanne (Switzerland)

IMPACT OF MENINGEAL DISSEMINATION (MD) ON OUTCOME IN PRIMARY CNS LYMPHOMA IN THE G-PCNSL-SG1 TRIAL
A. Korfel et al., Berlin (Germany)

IS PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) REALLY RESTRICTED TO THE CNS? EVALUATION OF SUBCLINICAL SYSTEMIC INVOLVEMENT WITH PCR
E. Thiel et al., Berlin (Germany)

HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION AS FIRST-LINE TREATMENT FOR PRIMARY CNS LYMPHOMA - UPDATED RESULTS OF A PILOT AND PHASE II STUDY
E. Schorb et al., Freiburg (Germany)
IMMUNOCHEMOTHERAPY WITH INTENSIVE CONSOLIDATION, WITHOUT BRAIN IRRADIATION, FOR PRIMARY CNS LYMPHOMA: A PILOT STUDY WITH PROGNOSTIC ASSESSMENT BY DIFFUSION-WEIGHTED MRI
J.L. Rubenstein et al., San Francisco, CA (USA)

INTENSIVE CHEMOTHERAPY WITH THIOTEPA, BUSULFAN, AND CYCLOPHOSPHAMIDE (TT-BU-CY) WITH HEMATOPOIETIC STEM CELL RESCUE (Tt+HCR) IN RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) OR INTRAOCULAR LYMPHOMA (IOL): A RETROSPECTIVE STUDY OF 74 CASES
C. Soussain et al., Saint-Cloud (France)

LONG-TERM COGNITIVE OUTCOME IN PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL): A TRANS-ATLANTIC MULTI-CENTER STUDY
N.D. Doolittle et al., Portland, OR (USA)

RISK FACTOR ANALYSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) FOR FOLLICULAR LYMPHOMA (FL). A RETROSPECTIVE STUDY ON BEHALF OF THE EBMT (THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION) LYMPHOMA WORKING PARTY AND THE CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) LYMPHOMA WORKING COMMITTEE
A. Sureda et al., Cambridge (UK)

ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) PROGRESSING AFTER AUTOLOGOUS TRANSPLANTATION (AUTOHCT). ON BEHALF OF THE WRITING COMMITTEE, CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH (CIBMTR), MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WI
T. Fenske et al., Milwaukee, WI (USA)

REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: THE EBMT EXPERIENCE
S.P. Robinson et al., Bristol (UK)

ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR CHEMOREFRACTORY T-CELL LYMPHOMA: ROLE OF HIGH INTENSITY CONDITIONING
B. Glass, Hamburg (Germany)

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EXTRANODAL NK/T-CELL LYMPHOMA, NASAL-TYPE: THE JAPAN SOCIETY FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (SHCT) LYMPHOMA WORKING PARTY
R. Suzuki et al., Nagoya (Japan)

BENDAMUSTINE IN COMBINATION WITH FLUDARABINE AND RITUXIMAB: A PHASE I-II NOVEL NONMYELOABLATIVE CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION (AST) IN PATIENTS WITH LYMPHOID MALIGNANCIES
J.F. Khouri et al., Houston, TX (USA)

IS MARROW BIOPSY STAGING FOR HD AND DLBCL OBSOLETE IN THE PET-CT ERA?
A.B. Khan et al., London (UK)

THE GERMINAL CENTER B-CELL SIGNATURE IS ASSOCIATED TO A HIGHER [18F]-FDG UPTAKE AND IMPROVES THE PROGNOSIS VALUE OF PET SCAN IN DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL) TREATED BY RITUXIMAB (R) AND ANTHRACYCLINES-BASED CHEMOTHERAPY
F. Jardin et al., Rouen (France)

FDG-PET TO GUIDE RADIOTHERAPY IN ADVANCED-STAGE HODGKIN LYMPHOMA PATIENTS WITH RESIDUAL BULKY DISEASE AFTER CHEMOTHERAPY: RESULTS OF THE GHSG HD15 TRIAL
A. Engert et al., Cologne (Germany)

PET-CT OF FOLLICULAR LYMPHOMA IN PATIENTS TREATED IN THE PRIMA STUDY: CENTRAL REVIEW OF SCANS USING THE 5PS
C. Tychy-Pinel et al., Pierre Bénite (France)

INTERNATIONAL VALIDATION STUDY OF INTERPRETATION RULES AND PROGNOSTIC ROLE OF INTERIM-PET SCAN IN ADVANCED STAGE HODGKIN LYMPHOMA
A. Gallamini et al., Cuneo (Italy)
18:20 048 CLINICAL USEFULNESS AND PROGNOSTIC SIGNIFICANCE OF INTERIM 18F-FDG PET/CT FOR THE TREATMENT OF PERIPHERAL T CELL LYMPHOMAS
D.H. Yang et al., Jeollanam-do (Republic of Korea)

17:30 – 18:30 IMMUNODEFICIENCY AND LYMPHOMA (Cittadella Theater)
Chair: M. Ponzoni, Milan (Italy)

17:30 049 GENOMIC COPY NUMBER ABERRATIONS (CNA) AFFECTING THE OUTCOME OF IMMUNODEFICIENCY-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS (ID-DLBCL)
F. Bertoni et al., Bellinzona (Switzerland)

17:40 050 METHYLOME PROFILING OF POST-TRANSPLANT DIFFUSE LARGE B-CELL LYMPHOMAS (PT-DLBCL)
D. Capello et al., Novara (Italy)

17:50 051 EBV-POSITIVE AND EBV-NEGATIVE POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS: TWO DIFFERENT DISORDERS?
T. Tousseyn et al., Leuven (Belgium)

18:00 052 THE ACCURACY OF PET IN THE DETECTION OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)
D. Dierickx et al., Leuven (Belgium)

18:10 053 ADAPTED MANAGEMENT OF EBV REACTIVATION AFTER SOLID ORGAN TRANSPLANTATION: AN EFFECTIVE PREVENTION OF POST TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS (PTLD)? RESULTS OF THE LARGEST PROSPECTIVE STUDY ON 251 PATIENTS, AND COMPARISON WITH 820 TRANSPLANTED CONTROLS
S. Choquet et al., Paris (France)

18:20 054 PRIMARY CENTRAL NERVOUS SYSTEM (CNS) POST-TRANSPLANT LYMPHOPROLIFERATION (PTLD): AN INTERNATIONAL REPORT OF 52 CASES IN THE RITUXIMAB ERA
A.M. Evens et al., Worcester, MA (USA)
Thursday, June 16, 2011

08:00 – 08:30
POSTER SET UP I (Marquee Parco Ciani)

08:30 – 18:30
POSTER SESSION I* (Marquee Parco Ciani)
*printing of the posters sponsored by Mundipharma
Authors present during lunch time

08:00 – 08:45
MEET THE PROFESSOR (repetition of some of Wednesday sessions)

09:00 – 10:35
SESSION 4 - LYMPHOMA GENOMICS (room A and Marquee Parco Ciani)
Chair : R. Dalla-Favera, New York, NY (USA) and R. Siebert, Kiel (Germany)

09:00  055  Introductory lecture: R. Siebert, Kiel (Germany)
09:20  056  FUNCTIONAL CHARACTERIZATION OF AN 11Q24.3 GAIN CONTRIBUTING TO THE PATHOGENESIS OF DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY BLOCKING B-CELL MATURATION
P. Bonetti et al., Bellinzona (Switzerland)
09:35  057  PRDM1 IS A TUMOR SUPPRESSOR GENE IN NATURAL KILLER CELL MALIGNANCIES
W.C. Chan et al., Omaha, NE (USA)
10:05  059  IDENTIFICATION OF A “DELETION BLOCK” AT 13Q14 THAT PERTURBS MULTIPLE SIGNALING AND SURVIVAL PATHWAYS IN PRIMARY CLASSICAL HODGKIN LYMPHOMA
B. Chapuy et al., Boston, MA (USA)

09:00 – 10:30
“CASE DISCUSSION” SESSIONS (3 parallel sessions: room B I, B II, USI Auditorium)

HODGKIN LYMPHOMA (room B I)
Chair: C. Moskowitz, New York, NY (USA)
Presenter: D. Villa, Vancouver, B.C. (Canada)
Discussants: V. Diehl, Cologne (Germany) and T. Illidge, Manchester (UK)

T-CELL (room B II)
Chair: S.T. Rosen, Chicago, IL (USA)
Presenter: R. Klasa, Vancouver, B.C. (Canada)
Discussants: P.L. Zinzani, Bologna (Italy) and J.M. Vose, Omaha, NE (USA)

CLL (USI Auditorium, Lugano University)
Chair: G. Gaidano, Novara (Italy)
10:35 – 10:55
**COFFEE BREAK** (Marquee Parco Ciani)

10:55 – 12:00
**SESSION 5 – LYMPHOMA AND THE IMMUNE SYSTEM**
(room A, B, C and Marquee Parco Ciani)
Chair: F. Stevenson, Southampton (UK)

10:55 061 Introductory lecture: F. Stevenson, Southampton (UK)

11:15 062 IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS
J. Brody et al., Stanford, CA (USA)

11:30 063 A PHASE II STUDY OF CT-011, AN ANTI-PD-1 ANTIBODY, AFTER AUSCT IN RECURRENT/REFRACTORY DLBCL: FIRST ANALYSIS OF PROGRESSION-FREE-SURVIVAL (PFS), OVERALL SURVIVAL (OS) AND TOXICITY (TOX)
L. Gordon et al., Chicago, IL (USA)

11:45 064 PROMISING RESULTS OF AN ANTI-CCR4 ANTIBODY, KW-0761, FOR RELAPSED ADULT T-CELL LEUKEMIA-LYMPHOMA (ATL)
K. Tobinai et al., Tokyo (Japan)

12:00 – 13:00
**LUNCH AND POSTER VIEWING** (Marquee Parco Ciani)

13:00 – 13:50 002 **RAPPAPORT LECTURE** (room A, B, C and Marquee Parco Ciani)
MODELING HUMAN LYMPHOMAGENESIS IN MICE
K. Rajewsky, Boston, MA (USA)
Chair: B.N. Nathwani, Los Angeles, CA (USA)

13:55 – 15:30
**SESSION 6 - TARGETING THE LYMPHOMA CELL SURFACE**
(room A, B, C and Marquee Parco Ciani)
Chair: P.W.M. Johnson, Southampton (UK) and J.P. Leonard, New York, NY (USA)

13:55 065 Introductory lecture: P.W.M. Johnson, Southampton (UK)

14:15 066 RESULTS FROM A PHASE I/II STUDY (BO20999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMA
G. Salles et al., Pierre Bénite (France)

14:30 067 ANTI-CD40 MONOCLONAL ANTIBODY LUCATUMUMAB EXHIBITS ANTI-TUMOR ACTIVITY IN FOLLICULAR LYMPHOMA AND OTHER LYMPHOMA SUBTYPES: PHASE I/II PRELIMINARY FINDINGS
A. Freedman et al., Boston, MA (USA)

14:45 068 BLINATUMOMAB (CD3/CD19 BITE® ANTIBODY) RESULTS IN A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) INCLUDING MCL AND DLBCL
R. Bargou, Würzburg (Germany)

15:00 069 INOTUZUMAB OZOGAMICIN (INO, CMC-544) IN PATIENTS WITH INDOLENT B-CELL NHL REFRACTORY TO RITUXIMAB (R), R PLUS CHEMOTHERAPY, OR RADIOIMMUNOTHERAPY (RIT)
A. Gay et al., Hackensack, NJ (USA)

15:15 070 PHASE I/II STUDY OF THE ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE SAR3419 ADMINISTERED WEEKLY TO PATIENTS (PTS) WITH RELAPSED / REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (NHL)
B. Coiffier et al., Pierre Bénite (France)

15:30 – 15:50
**COFFEE BREAK** (Marquee Parco Ciani)

15:50 – 17:20
**SESSION 7 – AGGRESSIVE LYMPHOMA** (room A and Marquee Parco Ciani)
Chair: M. Pfreundschuh, Homburg (Germany) and L.H. Sehn, Vancouver, C.B. (Canada)

15:50 071 MYC + AGGRESSIVE-B-CELL LYMPHOMAS: NOVEL THERAPY OF UNTREATED BURKITT LYMPHOMA (BL) AND MYC + DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH DA-EPOCH-R
K. Dunleavy et al., Bethesda, MD (USA)

16:05 072 A RANDOMIZED MULTICENTRE PHASE III STUDY FOR FIRST LINE TREATMENT OF YOUNG PATIENTS WITH HIGH RISK (AAIPI 2-3) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RITUXIMAB (R) PLUS DOSE-ENSE CHEMOTHERAPY CHOEP14/MEGACHOP14 WITH OR WITHOUT INTENSIFIED HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT), RESULTS OF DLCL04 TRIAL OF ITALIAN LYMPHOMA FOUNDATION (FIL)
U. Vitolo et al., Turin (Italy)

16:20 073 CONVENTIONAL CHEMOIMMUNOTHERAPY (R-CHOEP-14) OR HIGH-DOSE THERAPY (R-MEGA-CHOEP) FOR YOUNG, HIGH-RISK PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: FINAL RESULTS OF THE RANDOMIZED MEGA-CHOEP-TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN
16:35 074 RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – PRELIMINARY ANALYSIS
J.D. Hainsworth et al., Nashville, TN (USA)

16:50 075 SALVAGE REGIMEN WITH AUTOLOGOUS STEM CELL TRANSPLANTATION WITH OR WITHOUT RITUXIMAB MAINTENANCE FOR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); CORAL FINAL REPORT
C. Gisselbrecht et al., Paris (France)

17:05 076 AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS BENEFICIAL FOR PATIENTS RELAPSING AFTER R-CHOP AND WHO RESPOND TO SALVAGE CHEMOTHERAPY
S. Moore et al., London (UK)

15:50 – 18:30
SESSION 8 – PATHOLOGY & CLINICOPATHOLOGICAL CORRELATIONS (room B)
Chair: E.S. Jaffe, Bethesda, MD (USA) and S.A. Pileri, Bologna (IT)

15:50 077 THE RELIABILITY OF IMMUNOHISTOCHEMICAL ANALYSIS OF TUMOR MICROENVIRONMENT IN FOLLICULAR LYMPHOMA; A VALIDATION STUDY FROM THE LUNENBURG LYMPHOMA BIOMARKER CONSORTIUM (LLBC)
D. De Jong et al., Amsterdam (Netherlands)

16:05 078 DEVELOPMENT AND APPLICATION OF A NEW IMMUNOPHENOTYPIC ALGORITHM FOR MOLECULAR CLASSIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); REPORT FROM AN INTERNATIONAL DLBCL RITUXIMAB-CHOP CONSORTIUM PROGRAM STUDY
C. Visco et al., Vicenza (Italy)

16:20 079 DIFFERENTIAL GENE EXPRESSION PATTERNS IN EXTRANODAL SUBSETS OF NON-GCB DIFFUSE LARGE B-CELL LYMPHOMA
T.M. Green et al., Odense (Denmark)

16:35 080 GENE EXPRESSION PROFILING (GEP) AND NOT IMMUNOCHEMICAL ALGORITHMS PREDICTS PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP
G. Gutiérrez et al., Barcelona (Spain)

16:50 081 CONCURRENT BCL2 AND MYC TRANSLOCATIONS IN A PROSPECTIVE COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
A.O. Gang et al., Herlev (Denmark)

17:05 082 THE COMBINATION OF STAT3, CSE1L AND MYC-TRANSLOCATION FORMS A NEW DIAGNOSTIC ALGORITHM WHICH DISTINGUISHES BURKITT FROM DIFFUSE LARGE B-CELL LYMPHOMA AND PREDICTS OUTCOME
M. Tinguely et al., Zurich (Switzerland)

17:20 083 OCCURRENCE OF THE T(14;18)(Q32;Q21) AND ITS VARIANTS IN CHRONIC B-CELL LYMPHOPROLIFERATIVE DISORDERS OTHER THAN FOLLICULAR LYMPHOMA
L. Baseggio et al., Pierre Bénite (France)

17:35 084 INTEREST OF T(14;18) DETECTION FOR THE MANAGEMENT OF FOLLICLE CENTER LYMPHOMA PRESENTING AS SKIN LESIONS: 53 CASES STUDY
A. Pham-Ledard et al., Bordeaux (France)

17:50 085 BCL2, BCL6, MYC, CCND1, MALT1 AND BCL10 GENE RERANGEMENTS IN PRIMARY TESTICULAR LYMPHOMAS DETECTED BY FLUORESCENT IN SITU HYBRIDIZATION WITH SPLIT SIGNAL PROBES
S. Uccella et al., Varese (Italy)

18:05 086 TISSUE MICROARRAY IN DLBCL PATIENTS RECEIVING CHOP-R CHEMOIMMUNOTHERAPY SHOWS SURVIVAL BENEFIT FOR COEXPRESSION OF LMO2/ BCL6 AND POOR OUTCOME FOR EBER-ISH POSITIVE PATIENTS
C. Keane et al., Brisbane (Australia)

18:20 087 THE MOLECULAR HISTORY OF RICHTER SYNDROME
D. Rossi et al., Novara (Italy)

15:50 – 18:30
SESSION 9 – PEDIATRIC LYMPHOMA (room C)
Chair: S. Morris, Memphis, TN (USA) and A. Reiter, Giessen (DE)

15:50 088 WITH THE LMB AND BFM PROTOCOLS, CHILDREN AND ADOLESCENTS WITH B-CELL NON HODGKIN’S LYMPHOMA AND MATURE B-CELL LEUKEMIA HAVE SIMILAR SURVIVAL
C. Patte et al., Villejuif (France)

16:05 089 IN CHILDHOOD B-CELL NON HODGKIN’S LYMPHOMA (B-NHL) AND MATURE B-CELL ACUTE LEUKEMIA (B-AL) WITH CNS DISEASE AT DIAGNOSIS, PATIENTS
WITH BLASTS IN CSF ARE AT HIGHER RISK OF EVENT
V. Minard-Colin et al., Villejuif (France)

SAFETY AND PHARMACOKINETICS (PK) OF RITUXIMAB (R) IN COMBINATION
WITH FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS (C+A) WITH
STAGE III/IV MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT
M.J. Barth et al., Buffalo, NY (USA)

ANALYSIS OF TREATMENT FAILURE IN PATIENTS TREATED FOR NHL-B/B-ALL
IN POLISH PEDIATRIC LEUKEMIA/LYMPHOMA STUDY GROUP
E. Lato-Grażyńska et al., Wrocław (Poland)

EXCELLENT OUTCOME IN AGGRESSIVE NON HODGKIN'S LYMPHOMA IN
ADOLESCENTS AND YOUNG ADULTS TREATED WITH CHOP-BASED REGIMENS
IN DSHNHL TRIALS: AGE IS NOT A RISK FACTOR IN PATIENTS BELOW 50 YEARS
L.H. Trümper et al., Göttingen (Germany)

ALK TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF NHL
S. Morris, Memphis, TN (USA)

ANTI-ALK ANTIBODIES IN CHILDREN WITH LYMPHOMA WITH VARIANT ALK
TRANSLOCATIONS
C. Damm-Welk et al., Giessen (Germany)

MOLECULAR CHARACTERIZATION OF MATURE B-CELL LYMPHOMAS IN
CHILDREN: A COOPERATIVE STUDY OF MMML AND THE NHL-BFM GROUP
I. Salaverria et al., Kiel (Germany)

AMPLIFICATION OF CHROMOSOME 13Q31 IS ASSOCIATED WITH MIR-17
OVEREXPRESSION AND RELAPSE IN PEDIATRIC BURKITT LYMPHOMA
R.R. Miles et al., Salt Lake City, UT (USA)

MINIMAL DISSEMINATED DISEASE/RESIDUAL DISEASE IN CHILDREN AND
ADOLESCENTS WITH MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
MAY IMPACT THE RISK OF RELAPSE: A CHILDREN'S ONCOLOGY GROUP REPORT
B. Shiramizu et al., Honolulu, HI (USA)

THE NUMBER OF PREVIOUS TREATMENT LINES HAS NO IMPACT ON THE
OUTCOME AFTER HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL
RESCUE WITH BEAM FOR RELAPSED FOLLICULAR LYMPHOMA
S. Montoto et al., London (UK)

AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR
TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA: A REPORT OF THE
CANADIAN BLOOD AND MARROW TRANSPLANT GROUP (CBMTG)
D. Villa et al., Vancouver, B.C. (Canada)

AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) AS UPRIGHT OR
SALVAGE THERAPY FOR NON-CUTANEOUS T CELL LYMPHOMA (TCL):
THE M.D. ANDERSON CANCER CENTER (MDACC) EXPERIENCE
A. Beitinjaneh et al., Houston, TX (USA)

LONG TERM DISEASE CONTROL AND OVERALL SURVIVAL AFTER EARLY DOSE
INTENSIFICATION IN T-NHL DEPEND ON SPECIFIC ENTITIES
R. Marks et al., Freiburg (Germany)

UPDATE OF THE NORDIC MCL2 TRIAL UPDATE: 10-YEAR SURVIVAL 57%
FOLLOWING INTENSIVE IMMUNOCHEMOTHERAPY AND ASCT, BUT LATE
RELAPSES DO OCCUR
C.H. Geisler et al., Copenhagen (Denmark)

TOTAL BODY IRRADIATION (TBI) IN THE CONDITIONING REGIMEN OF
AUTOLOGOUS STEM CELL TRANSPLANTATION REDUCES THE RISK OF RELAPSE
OF MANTLE CELL LYMPHOMA TRANSPLANTED IN PARTIAL REMISSION: A
RETROSPECTIVE STUDY FROM THE LYMPHOMA WORKING PARTY OF THE
EBMT
O. Hermine et al., Paris (France)

EBV POSITIVE DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY IS AN
AGGRESSIVE B CELL NEOPLASM WITH A POST GERMINAL CENTER B CELL
PHENOTYPE AND CHARACTERIZED BY NFKB PATHWAY ACTIVATION.

17:40 105  COMPREHENSIVE GERIATRIC ASSESSMENT-ADAPTED CHEMOTHERAPY IN ELDERLY PATIENTS (> 70 YEARS) WITH DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA (DLBCL): FINAL RESULTS AND LONG TERM FOLLOW-UP
S. Montes-Moreno et al., Madrid (Spain)

17:50 106  R-CHOP14 COMPARED TO R-CHOP21 IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF THE SECOND INTERIM ANALYSIS OF THE LNH03-6B GELA STUDY
M. Spina et al., Aviano (Italy)

18:00 107  EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496
A.M. Evens et al., Worcester, MA (USA)

18:10 108  AUTOLOGOUS STEM CELL TRANSPLANT IS FEASIBLE IN VERY ELDERLY PATIENTS WITH LYMPHOMA AND LIMITED COMORBIDITY
R.L. Elstrom et al., New York, NY (USA)

17:30 – 18:20  NEW DRUG COMBINATIONS (USI Aula Magna, Lugano University)
Chair: J.W. Friedberg, Rochester, NY (USA)

17:30 109  ORAL LENALIDOMIDE PLUS 4 DOSES OF RITUXIMAB INDUCED PROLONGED REMISSIONS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMPLETED PHASE I/II CLINICAL TRIAL
M. Wang et al., Houston, TX (USA)

17:40 110  COMBINATION OF LENALIDOMIDE WITH R-CHOP (R2CHOP) IS SAFE AND EFFECTIVE AS INITIAL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS - A PHASE I/II STUDY
G. Nowakowski et al., Rochester, MN (USA)

17:50 111  PHASE II TRIAL OF CISPLATIN PLUS ETOPOSIDE PLUS GEMCITABINE PLUS SOLUMEDROL (PEGS) IN PERIPHERAL T-CELL NON-HODGKIN LYMPHOMA (SWOG S0350)
D. Mahadevan et al., Tucson, AZ (USA)

18:00 112  FINAL RESULTS OF A PHASE I-II CLINICAL TRIAL OF OXALIPLATIN, FLUDARABINE, CYTARABINE, AND RITUXIMAB (OFAR) COMBINATION THERAPY IN PATIENTS WITH AGGRESSIVE, RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND RICHTER SYNDROME (RS)
A.M. Tsimberidou et al., Houston, TX (USA)

18:10 113  SHORT COURSE FLUDARABINE, MITOXANTRONE, RITUXIMAB FOLLOWED BY 90Y-IBRITUMOMAB TIUXETAN IN UNTREATED INTERMEDIATE/HIGH-RISK FOLLICULAR LYMPHOMA: A PHASE II TRIAL
P.L. Zinzani et al., Bologna (Italy)

17:30 – 18:20  PLASMA CELL DISORDERS AND WALDENSTRÖM MACROGLOBULINEMIA (Cittadella Theater)
Chair: V. Rajkumar, Rochester, MN (USA)

17:30 114  CYTOGENETIC ABNORMALITIES IN A COHORT OF 175 PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA BEFORE TREATMENT: CLINICAL AND BIOLOGICAL CORRELATIONS
F. Nguyen-Khac et al., Paris (France)

17:40 115  MICRORNA-9* REGULATES HISTONE ACETYLATION IN WALDENSTRÖM’S MACROGLOBULINEMIA
A.M. Roccaro et al., Boston, MA (USA)

17:50 116  FAMILIAL DISEASE STATUS IS ASSOCIATED WITH AN INFERIOR TREATMENT OUTCOME IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA
S.R. Teon et al., Boston, MA (USA)

18:00 117  RESPONSES TO SINGLE-AGENT CARFILZOMIB (CFZ) ARE NOT AFFECTED BY CYTOGENETICS IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM)
A.J. Jakubowiak et al., Ann Arbor, MI (USA)

18:10 118  IL-6 MEDIATED HEMATOPOIESIS DEVIATION FAVORS APRIL PRODUCTION DURING MULTIPLE MYELOMA INVASION OF BONE MARROW
B. Huard et al., Geneva (Switzerland)
Friday, June 17, 2011

08:00 – 08:30
POSTER SET UP II (Marquee Parco Ciani)

08:30 – 18:30
POSTER SESSION II * (Marquee Parco Ciani)
* printing of the posters sponsored by Mundipharma
Authors present during lunch time
270 – 281
PEdiATRIC LYMPHOMA
282 – 294
hODGKIN LYMPHOMA
295 – 319
INDOLENT LYMPHOMA
320 – 345
AGGRESSIVE LYMPHOMA
346 – 361
NEW DRUGS

08:00 – 08:45
MEET THE PROFESSOR (repetition of some of Wednesday sessions)

VI
MICRO-ARRAYS FOR DUMMIES (room A)
M.F. Fey, Berne (Switzerland)

XV
PRIMARY CUTANEOUS LYMPHOMAS (room B I)
R. Willemze, Leiden (Netherlands)

XI
DISTINGUISHING BURKITT LYMPHOMA FROM DIFFUSE LARGE B-CELL LYMPHOMA (room B II)
A. Jack, Leeds (UK)

VII
THE ROLE OF THE MICROENVIRONMENT IN LYMPHOID CANCERS (USI Auditorium, Lugano University)
R.D. Gascoyne, Vancouver, B.C. (Canada)

XIII
THE ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF LYMPHOMA (USI Aula Magna, Lugano University)
R. Levy, Stanford, CA (USA)

XIV
T AND NK CELL LYMPHOPROLIFERATIVE DISORDERS (Cittadella Theater)
S.T. Rosen, Chicago, IL (USA)

09:00 – 10:30
SESSION 10 – CLL (room A, B, C and Marquee Parco Ciani)
Chair: B.D. Cheson, Washington, D.C. (USA) and J. Gribben, London (UK)

09:00 119
DEl(13q14.3) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH 13Q DELETION ALONE OR NORMAL KARYOTYPE
F. Bertoni et al., Bellinzona (Switzerland)

09:15 120
RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY
P. Hillmen et al., Leeds (UK)

09:30 121
FCR VS AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A COMPARISON OF TWO PROSPECTIVE STUDIES OF THE GCLLSG
P. Dreger et al., Heidelberg (Germany)

09:45 122
THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND TOLERABLE IN PATIENTS WITH POOR-RISK CLL: INTERIM RESULTS FROM A PHASE IB/II STUDY
S. O’Brien et al., Houston, TX (USA)

10:00 123
SEQUENTIAL THERAPY OF FLUDARABINE, MITOXANTRONE AND CYCLOPHOSPHAMIDE (FMC) INDUCTION FOLLOWED BY ALEMTUZUMAB CONSOLIDATION IS EFFECTIVE AND SAFE IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) - RESULTS FROM A MULTICENTER PHASE II TRIAL OF THE GERMAN CLL STUDY GROUP
G. Hopfinger et al., Salzburg (Austria)

10:15 124
CLADRIBINE GIVEN SUBCUTANEously FOR FIVE DAYS HAS EQUIVALENT EFFICACY TO AND LOWER TOXICITY THAN CLADRIBINE GIVEN FOR SEVEN CONSECUTIVE DAYS IN PATIENTS WITH HAIRY CELL LEUKEMIA
F. Forconi et al., Siena (Italy)

09:00 – 10:30
“CASE DISCUSSION” SESSIONS (3 parallel sessions)

AGGRESSIVE LYMPHOMA (room B I)
Chair: C. Geisler, Copenhagen (Denmark)
Presenter: L. Sehn, Vancouver, B.C. (Canada)
Discussants: J.F. Seymour, Melbourne (Australia) and M.A. Shipp, Boston, MA (USA)

INDOLENT LYMPHOMA (room B II)
Chair: J.W. Friedberg, Rochester, NY (USA)
Presenter: M.H. van Oers, Amstendam (Netherlands)
Discussants: M. Rummel, Giessen (Germany) and G. Salles, Pierre Bénite (France)

EXTRANODAL LYMPHOMA (USI Auditorium, Lugano University)
Chair: M.K. Gospodarowicz, Toronto (Canada)
Presenter: M.-J. Kersten, Amsterdam (Netherlands)
Discussants: A. Lopez-Guillermo, Barcelona (Spain) and E. Zucca, Bellinzona (Switzerland)

10:30 – 10:50
COFFEE BREAK (Marquee Parco Ciani)

10:50 – 12:05
SESSION 11 - T-CELL LYMPHOMA (room A, B, C and Marquee Parco Ciani)
Chair: M. Federico, Modena (Italy) and J.M. Vose, Omaha, NE (USA)

10:50 125 DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL)
A. Shustov et al., Seattle, WA (USA)

11:05 126 PRELIMINARY RESULTS FROM AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF BENDAMUSTINE IN RELAPSED OR REFRACTORY T-CELL LYMPHOMA FROM THE FRENCH GOELAMS GROUP: THE BENTLY TRIAL
G. Damaj et al., Amiens (France)

11:20 127 LONG-TERM OUTCOME OF ADULTS WITH SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA TREATED WITHIN THE GROUPE D’ETUDE DES LYMPHOMES DE L’ADULTE (GELA) TRIALS
D. Sibon et al., Paris (France)

11:35 128 CHOEP-14 AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: PROSPECTIVE STUDY BY THE NORDIC LYMPHOMA GROUP (NLG-T-01)
G.F. Lauritzen et al., Oslo (Norway)

11:50 129 ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA: CLINICAL AND HISTOLOGICAL FINDINGS FROM THE INTERNATIONAL PERIPHERAL T-CELL LYMPHOMA PROJECT
J.M. Delabie et al., Oslo (Norway)

12:05 – 13:00
LUNCH AND POSTER VIEWING (Marquee Parco Ciani)

13:00 – 13:55 003 ULTMANN LECTURE sponsored by ASCO (room A, B, C and Marquee Parco Ciani)
TREATMENT OF MYELOMA: CURE VERSUS CONTROL
V. Rajkumar, Rochester, MN (USA)
Chair: J.O. Armitage, Omaha, NE (USA)

13:55-15:00
SESSION 12 – LYMPHOMA AND APOPTOSIS (room A and Marquee Parco Ciani)
Chair: O.A. O’Connor, New York, NY (USA)

13:55 130 Introductory lecture: O.A. O’Connor, New York, NY (USA)

14:15 131 ACTIVATION OF THE STAT3 SIGNALING PATHWAY PREDICTS POOR SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH R-CHOP
K. Fu et al., Omaha, NE (USA)

14:30 132 METABOLIC TARGETING IN LYMPHOMA THERAPY
C.A. Schmitt et al., Berlin (Germany)

14:45 133 A CYCLIN-D1 INTERACTION WITH BAX UNDERLIES ITS ONCOGENIC ROLE AND POTENTIAL AS A THERAPEUTIC TARGET IN MANTLE CELL LYMPHOMA
J.A. Martinez-Climent et al., Pamplona (Spain)

15:00 – 15:20
COFFEE BREAK (Marquee Parco Ciani)

15:20 – 16:35
SESSION 13 – INDOLENT LYMPHOMA (room A, B, C and Marquee Parco Ciani)
Chair: S. Montoto, London (UK) and E. Zucca, Bellinzona (Switzerland)

15:20 134 INTERNATIONAL PHASE III STUDY OF CHLORAMBUCIL VERSUS FLUDARABINE AS INITIAL THERAPY FOR WALDENSTROM’S MACROGLOBULINEMIA AND RELATED DISORDERS:RESULTS IN 414 PATIENTS ON BEHALF OF FCGCLL/WM, GOELAMS, GELA AND NCRi
V. Leblond et al., Paris (France)

15:35 135 R-CVP VS R-CHOP VS R-FM FOR THE INITIAL TREATMENT OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS OF FOLL05 III TRIAL
M. Federico et al., Modena (Italy)

15:50 136 RITUXIMAB (R) IN COMBINATION WITH INTERFERON-A2A (IFN) SHOWS BETTER RESPONSE THAN SINGLE R IN PATIENTS WITH FOLLICULAR OR OTHER CD20+ LOW-GRADE (INDOLENT) LYMPHOMA. A RANDOMIZED PHASE III
LENALIDOMIDE PLUS RITUXIMAB IS A HIGHLY EFFECTIVE AND WELL-TOLERATED BIOLOGIC THERAPY IN UNTREATED INDOLENT B CELL NON-HODGKINS LYMPHOMA
N. Fowler et al., Houston, TX (USA)

HEMATOLOGICAL RESPONSE TO ANTIVIRAL TREATMENT IN 94 PATIENTS WITH INDOLENT B-CELL LYMPHOMAS ASSOCIATED WITH HEPATITIS C VIRUS INFECTION: A STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)
L. Arcaini et al., Pavia (Italy)

CONTROVERSY II: IS INTERIM PET USEFUL IN PLANNING TREATMENT FOR DLBCL?
(room A, B, C and Marquee Parco Ciani)
C. Haioun, Creteil Cedex (France) vs C. Moskowitz, New York, NY (USA)
Chair: A. Gallamini, Cuneo (Italy)

REPORT OF THE 11-ICML CLOSED WORKSHOP
(room A, B, C and Marquee Parco Ciani)
T.A. Lister, London (UK)

FAREWELL APERITIF (Marque Parco Ciani)
08:00 – 08:50

FOCUS ON… SESSIONS (2 parallel sessions)

MONOCLONAL ANTIBODIES (room A)
Chair: R. Levy, Stanford, CA (USA)

08:00 141  LYMHPHA PATIENTS TREATED WITH RITUXIMAB-CONTAINING REGIMENS DO NOT ACHIEVE PROTECTIVE SEROLOGICAL RESPONSES TO H1N1 INFLUENZA VIRUS AFTER VACCINATION
O.E. Yri et al., Oslo (Norway)

08:10 142  FcγR POLYMORPHISMS DO NOT INFLUENCE RESPONSE TO RITUXIMAB IN ASYMPTOMATIC, NON-BULKY FOLLICULAR LYMPHOMA; RESULTS FROM INTERGROUP TRIAL OF RITUXIMAB VS “WATCH AND WAIT”
L. Lowry et al., London (UK)

08:20 143  FC GAMMA RECEPTOR IIB ON HUMAN B CELLS PROMOTES RITUXIMAB INTERNALIZATION AND REDUCES CLINICAL EFFICACY
S.H. Lim et al., Southampton (UK)

08:30 144  RESULTS FROM A PHASE II STUDY (BOZ0999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMPHOMA
G. Cartron et al., Montpellier (France)

08:40 145  A PHASE 2B TRIAL COMPARING DACEKTUZUMAB + R-ICE VS PLACEBO + R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
L. Fayad et al., Houston, TX (USA)

08:00 – 08:50

PRIMARY MEDIASTINAL BCL (room B)
Chair: C. Thieblemont, Paris (France)

08:00 146  BORTEZOMIB (BTZ), IKK INHIBITOR ML120B, AND COMBINATION THERAPY INDUCE APOPTOSIS, INHIBIT NF-κB ACTIVATION, AND DECREASE SPECIFIC PROTEINS IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL)
R.R. Miles et al., Salt Lake City, UT (USA)

08:10 147  PET/CT RESPONSE ANALYSIS IN PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA (PMBL): PRELIMINARY RESULTS OF THE IELSG-26 STUDY
L. Ceriani et al., Bellinzona (Switzerland)

08:20 148  THE IMPACT OF R-VACOP-B AND THE PROGNOSTIC SIGNIFICANCE OF INTERIM FDG-PET/CT ON THE OUTCOME OF PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA- A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER COHORT
A. Avigdor et al., Tel-Hashomer (Israel)

08:30 149  MACOP-B+/− RITUXIMAB FOLLOWED BY INVOLVED MEDIASTINAL RADIOTHERAPY IS A SAFE AND HIGH EFFECTIVE THERAPY FOR PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA (PMBL): LONG TERM RESULTS AND LATE TOXICITY FROM A SINGLE ITALIAN CENTER
M. Martelli et al., Rome (Italy)

08:40 150  UNTREATED PRIMARY MEDIASTINAL B-CELL (PMBL) AND MEDIASTINAL GREY ZONE (MGZL) LYMPHOMAS: COMPARISON OF BIOLOGICAL FEATURES AND CLINICAL OUTCOME FOLLOWING DA-EPOCH-R WITHOUT RADIATION
K. Dunleavy et al., Bethesda MD (USA)

08:55 – 11:00

SESSION 14 - SIGNALLING PATHWAYS IN LYMPHOMA (room A)
Chair: F.E. Cotter, London (UK) and M.A. Shipp, Boston, MA (USA)

08:55 151  Introductory lecture: M.A. Shipp, Boston, MA (USA)

09:15 152  MULTICENTER PHASE II TRIAL OF MLN8237, AN INVESTIGATIONAL INHIBITOR OF AURORA A KINASE (AAK), IN PATIENTS (PTS) WITH AGGRESSIVE B-CELL AND T-CELL NON-HODGKIN LYMPHOMA (NHL)
J.W. Friedberg et al., Rochester, NY (USA)

09:30 153  THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY
R.H. Advani et al., Stanford, CA (USA)

09:45 154  PIM INHIBITION AS A RATIONAL THERAPEUTIC APPROACH IN DIFFUSE LARGE B-CELL LYMPHOMA
C. Gómez-Abad et al., Madrid (Spain)

10:00 155  TARGETING CAP-DEPENDENT TRANSLATION TO BYPASS PRO-SURVIVAL SIGNALING BY AKT AND THE PIM FAMILY KINASES IN NON-HODGKIN LYMPHOMA
J.H. Schatz et al., New York, NY (USA)
SESSION 15 – HODGKIN LYMPHOMA (room B)
Chair: G.P. Canellos, Boston, MA (USA) and M. Engert, Cologne (Germany)

09:00  159  GENETIC POLYMORPHISMS INFLUENCE THE RISK OF HODGKIN'S LYMPHOMA
O.E. Yri et al., Oslo (Norway)

09:15  160  DURABLE COMPLETE REMISSIONS IN A PIVOTAL PHASE 2 STUDY OF SGN-35
(BRENTUXIMAB VEDOTIN) IN PATIENTS WITH RELAPSED OR REFRACTORY
HODGKIN LYMPHOMA (HL)
A. Younes et al., Houston, TX (USA)

09:30  161  BIOMARKER ANALYSIS OF PIVOTAL PHASE II STUDY OF ORAL PANOBINOSTAT
(PAN) IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS
FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
S. Harrison et al., Melbourne (Australia)

09:45  162  EARLY DETERMINATION OF TREATMENT SENSITIVITY IN HODGKIN
LYMPHOMA: FDG-PET/CT AFTER ONE CYCLE OF THERAPY HAS A
HIGHER NEGATIVE PREDICTIVE VALUE THAN AFTER TWO CYCLES OF
CHEMOTHERAPY
M. Hutchings et al., Copenhagen (Denmark)

10:00  163  MULTICENTRE CLINICAL STUDY WITH EARLY TREATMENT INTENSIFICATION
IN HIGH-RISK HODGKIN LYMPHOMA (HL) PATIENTS, WITH A POSITIVE
FDG-PET SCAN AFTER TWO ABVD COURSES – GITIL HD0607 STUDY
A. Gallamini et al., Cuneo (Italy)

10:15  164  IGEV VS. IGEV+BORTEZOMIB (VELCADETM) BEFORE HIGH-DOSE
CONSOLIDATION THERAPY FOLLOWED BY AUTOLOGOUS STEM CELL
TRANSPLANTATION (ASCT) IN RELAPSED OR REFRACTORY HODGKIN
LYMPHOMA (HL): A RANDOMIZED PHASE II TRIAL OF THE FONDAZIONE
ITALIANA LINFOMI
M. Balsarotti et al., Rozzano Milano (Italy)

10:30  165  PARENTHOOD IN SURVIVORS OF HODGKIN LYMPHOMA (HL): AN
EORTC-GELA GENERAL POPULATION CASE-CONTROL STUDY
J.C. Kluin-Nelemans, Groningen (Netherlands)

10:45  166  GONADAL FUNCTION IN WOMEN AFTER TREATMENT OF EARLY
UNFAVOURABLE HODGKIN LYMPHOMA (HL). FIRST RESULTS OF THE
FERTILITY RESEARCH PROJECT WITHIN THE 5th TRIAL GENERATION, GERMAN
HODGKIN STUDY GROUP (GHSG)
K. Behringer et al., Cologne (Germany)

11:00  CLOSING REMARKS (room A and B)
Chair: F. Cavalli, Bellinzona (Switzerland)
J.O. Armitage, Omaha, NE (USA)